J, E., H, B., D, L., B, G., H, H., U, S., . . . T, L. (2023). Correction to: Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 34(11), 1975. https://doi.org/10.1007/s00198-023-06887-4
Chicago Style (17th ed.) CitationJ, Everts-Graber, Bonel H, Lehmann D, Gahl B, Häuselmann H, Studer U, Ziswiler HR, Reichenbach S, and Lehmann T. "Correction to: Comparison of Anti-fracture Effectiveness of Zoledronate, Ibandronate and Alendronate Versus Denosumab in a Registry-based Cohort Study." Osteoporosis International : A Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 34, no. 11 (2023): 1975. https://doi.org/10.1007/s00198-023-06887-4.
MLA (9th ed.) CitationJ, Everts-Graber, et al. "Correction to: Comparison of Anti-fracture Effectiveness of Zoledronate, Ibandronate and Alendronate Versus Denosumab in a Registry-based Cohort Study." Osteoporosis International : A Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, vol. 34, no. 11, 2023, p. 1975, https://doi.org/10.1007/s00198-023-06887-4.
